Cognition Therapeutics Presents Data at AAIC Highlighting Broad Neurological Impact of Zervimesine (CT1812) in Dementia with Lewy Bodies and Alzheimer’s Disease
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jul 28 2025
0mins
Source: Globenewswire
Zervimesine's Efficacy in DLB and Alzheimer's: Recent presentations at the Alzheimer’s Association International Conference highlighted zervimesine's positive effects on behavioral symptoms in dementia with Lewy bodies (DLB) and its ability to halt cognitive decline in Alzheimer's patients, particularly those identified through plasma p-tau217 levels.
Biomarker Support for Treatment Impact: Research indicates that zervimesine treatment influences biomarkers related to neuroinflammation and neurodegeneration, suggesting a beneficial impact on the underlying biology of Alzheimer's disease.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
